德展健康(000813) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥480,934,229.19, a decrease of 38.92% compared to ¥787,375,642.93 in the same period last year[9]. - Net profit attributable to shareholders was ¥120,802,841.01, down 32.09% from ¥177,880,864.50 year-on-year[9]. - Basic earnings per share decreased by 31.36% to ¥0.0545 from ¥0.0794 in the same period last year[9]. - Total operating revenue for the first quarter was CNY 480,934,229.19, a decrease of approximately 38.8% compared to CNY 787,375,642.93 in the same period last year[65]. - Net profit for the first quarter was CNY 120,802,841.01, a decline of 32.2% compared to CNY 177,880,864.50 in the previous year[68]. - The total comprehensive income for the period was -4,781,453.42 CNY, compared to 1,799,966.18 CNY in the previous period[79]. - The company reported a net loss of -4,781,453.42 CNY for the period, compared to a net profit of 1,799,966.18 CNY in the previous period[79]. Cash Flow and Assets - The net cash flow from operating activities increased significantly to ¥385,741,120.49, a rise of 49,575.07% compared to ¥776,528.55 in the previous year[9]. - The cash flow from operating activities showed a remarkable increase of 49,575.07%, reaching 385,741,120.49 RMB, mainly due to the collection of accounts receivable[25]. - As of March 31, 2019, the company's total current assets amounted to ¥5,018,832,866.28, an increase from ¥4,758,447,495.18 at the end of the previous year[45]. - The company's cash and cash equivalents decreased from ¥1,444,695,850.79 to ¥1,041,028,620.36 during the same period[45]. - The total cash inflow from operating activities was 951,154,755.35 CNY, compared to 661,543,422.37 CNY in the previous period[83]. - The total cash outflow from operating activities was 565,413,634.86 CNY, down from 660,766,893.82 CNY in the previous period[83]. - The ending balance of cash and cash equivalents was 619,216,079.95, down from 1,230,396,714.59 in the prior period[93]. - The company reported a decrease in cash and cash equivalents by 94,447,418.31 during the period[93]. Shareholder Information - The top ten shareholders held a significant portion of shares, with the largest shareholder holding 30.20%[13]. - The company completed its share repurchase plan, utilizing a total of 200 million RMB to buy back shares at a price not exceeding 12 RMB per share[26]. - The company repurchased a total of 23,612,228 shares, accounting for 1.0534% of the total share capital before the repurchase, with a total payment of approximately ¥200 million[33]. - The repurchased shares will be used for employee stock ownership plans or equity incentive plans, subject to board authorization[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,762,403,637.76, a decrease of 2.69% from ¥5,921,638,285.93 at the end of the previous year[9]. - The company's total assets as of March 31, 2019, were ¥5,762,403,637.76, compared to ¥5,921,638,285.93 at the end of the previous year[54]. - Total liabilities decreased from ¥640,152,430.60 to ¥365,661,202.00 during the same period[51]. - The company's total equity increased from ¥5,281,485,855.33 to ¥5,396,742,435.76[54]. - The company has no overdue commitments or securities investments during the reporting period[34][35]. Operational Developments - The company reported a significant increase in prepayments, which rose by 198.88% to 31,544,069.20 RMB due to increased technology development fees and project payments[25]. - Other receivables surged by 10,767.16% to 100,062,075.53 RMB, primarily due to payments made for cooperation earnest money[25]. - The company experienced a 47.09% increase in construction in progress, amounting to 81,024,345.59 RMB, attributed to increased investment in subsidiary production lines[25]. - The company’s subsidiary, Jialin Pharmaceutical, received a GMP certificate, allowing its new production base to commence operations[27]. - The company signed a strategic cooperation framework agreement with Hanma Group for equity acquisition and collaboration in research[27]. Financial Adjustments - The company reported a significant increase in current assets, totaling ¥2,076,909,614.31, an increase of ¥400,000,000.00[106]. - The company adjusted financial reporting, reclassifying certain financial products, impacting non-current assets by ¥400,000,000.00[105]. - The company has adjusted financial products previously classified as other current assets to trading financial assets under new financial instrument standards[113]. - The company has not applied the retrospective adjustment for the new financial instrument and lease standards[114]. Management and Governance - The chairman of the board is Zhang Yong, and the report was released on April 25, 2019[117]. - The first quarter report has not been audited[116]. - The report indicates that the company is focused on health and wellness sectors[115].